Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706899 · ClinicalTrials.gov registry record · Phase 1
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02706899 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 19 participants.
The verdict
NCT02706899, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).
Interventions
- DRUG Azacitidine
- DRUG vadastuximab talirine
- DRUG Placebo (for 33A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02706899
The ClinicalTrials.gov registry entry for NCT02706899 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT02706899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02706899 about?
NCT02706899 is a clinical study titled "Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS". This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).
What is the current status of trial NCT02706899?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2016-02. Estimated completion is 2017-11-06.
What interventions are being tested in trial NCT02706899?
The interventions under investigation include: Azacitidine (DRUG), vadastuximab talirine (DRUG), Placebo (for 33A) (DRUG).
Who is sponsoring clinical trial NCT02706899?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.